Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Next Previous
X
Search
Trial Profile

A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational
  • Acronyms OPT Extend
  • Sponsors Pfizer

    • Most Recent Events

    • 12 May 2018 Results (n=2867) assessing the long-term safety and durability of efficacy of tofacitinib in adults with moderate to severe chronic plaque psoriasis, were published in the British Journal of Dermatology.
    • 25 Oct 2017 Results of an open-label vaccine substudy (n=61) published in the Journal of the American Academy of Dermatology
    • 31 May 2017 This trial has been completed in Germany (End date:2016-06-22) as per European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top